Cargando…

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells

The PI3Kδ-inhibitor Idelalisib is approved for the treatment of Non-Hodgkin lymphoma. However, its use has been decreased within the last years due to deleterious infections such as cytomegalovirus and pneumocystis jirovecii. Here, we have investigated the effect of Idelalisib on human monocyte-deri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braun, Christiane, Schlaweck, Sebastian, Daecke, Solveig Nora, Brossart, Peter, Heine, Annkristin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571156/ https://www.ncbi.nlm.nih.gov/pubmed/34173009 http://dx.doi.org/10.1007/s00262-021-02988-3

Ejemplares similares

Elotuzumab spares dendritic cell integrity and functionality
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function
por: Heine, Annkristin, et al.
Publicado: (2015)

Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer
por: Heine, Annkristin, et al.
Publicado: (2023)

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
por: Adam, Etai, et al.
Publicado: (2017)

Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma
por: Koerber, Ruth-Miriam, et al.
Publicado: (2015)

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential
por: Barrachina, María N., et al.
Publicado: (2021)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K(δ) inhibitor idelalisib
por: Sandova, Veronika, et al.
Publicado: (2021)

Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning
por: Wolf, Dominik, et al.
Publicado: (2014)

Clinical and immunological effects of mRNA vaccines in malignant diseases
por: Heine, Annkristin, et al.
Publicado: (2021)

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo
por: Palazzo, Adam, et al.
Publicado: (2018)

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
por: Krause, Günter, et al.
Publicado: (2018)

Two cases of EBV infection preceding lymphoma
por: Saal, Jonas, et al.
Publicado: (2022)

Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report
por: Koerber, Ruth-Miriam, et al.
Publicado: (2021)

Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
por: Somoza, John R., et al.
Publicado: (2015)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021)

Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)

RNA Vaccines in Cancer Treatment
por: Bringmann, Anita, et al.
Publicado: (2010)

Dexamethasone induced inhibition of Dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways
por: Kotthoff, Philipp, et al.
Publicado: (2017)

G-quadruplexes: a promising target for cancer therapy
por: Kosiol, Nils, et al.
Publicado: (2021)

BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells
por: De Magis, Alessio, et al.
Publicado: (2021)

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses
por: Alflen, Astrid, et al.
Publicado: (2018)

PI3Kinase-p110δ Overexpression Impairs Dendritic Morphogenesis and Increases Dendritic Spine Density
por: Hood, Veronica L., et al.
Publicado: (2020)

Baseline immune signature score of Tregs × HLA-DR(+)CD4(+) T cells × PD1(+)CD8(+) T cells predicts outcome to immunotherapy in cancer patients
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
por: Xiang, Qiong, et al.
Publicado: (2021)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines
por: Sklarz, L.-M., et al.
Publicado: (2020)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients
por: Southworth, Thomas, et al.
Publicado: (2016)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Hyper-activated PI3K-δ in immunodeficiency
por: Heurtier, Lucie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_atk6k9fujou1rd87m9jsp6vrrt